Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Determination of dialysis dose: a clinical comparison of methods.

Ahrenholz P, Taborsky P, Bohling M, Rawer P, Ibrahim N, Gajdos M, Machek P, Sagova M, Gruber H, Moucka P, Rychlik I, Leimenstoll G, Vyskocil P, Toenne G, Possnickerova J, Woggan J, Riegel W, Schneider H, Wojke R.

Blood Purif. 2011;32(4):271-7. doi: 10.1159/000330340. Epub 2011 Aug 23.

2.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators.

Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.

3.

Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.

Krane V, Berger M, Lilienthal J, Winkler K, Schambeck C, Wanner C; German Diabetes and Dialysis Study Investigators.

Clin J Am Soc Nephrol. 2010 May;5(5):874-81. doi: 10.2215/CJN.01170209. Epub 2010 Feb 25.

4.

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

Hutchison AJ, Barnett ME, Krause R, J, Siami GA; Lanthanum Carbonate Study Group.

Clin Nephrol. 2009 Mar;71(3):286-95.

PMID:
19281739
5.

Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients.

Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE; PHV Study Group.

Gut. 2002 Sep;51(3):429-33.

6.

Prevalence of and risk factors for hepatitis G (HGV) infection in haemodialysis patients: a multicentre study.

Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE; PHV Study Group.

Nephrol Dial Transplant. 2002 Feb;17(2):271-5.

7.

Does prolonged oral treatment with sustained-release morphine tablets influence immune function?

Palm S, Lehzen S, Mignat C, Steinmann J, Leimenstoll G, Maier C.

Anesth Analg. 1998 Jan;86(1):166-72.

PMID:
9428873
8.

Effect of renal function on cytokine secretion of monocytes and lymphocytes.

Leimenstoll G, Zabel P, Birkner T, Heyl K, Preusse D, Niedermayer W.

Nephrol Dial Transplant. 1994;9(5):493-8.

PMID:
8090329
9.

Cytokine secretion capacity of mononuclear cells in renal transplant recipients: the effect of two different dose schedules.

Leimenstoll G, Engemann R, Gassel J, Hoffmann S, Preusse D, Schlag H, Niedermayer W.

Transplant Proc. 1993 Aug;25(4):2666-8. No abstract available.

PMID:
8356715
10.

Donor-transmitted non-Hodgkin's lymphoma after renal transplantation--a case report.

Schütt G, Engemann R, Gassel HJ, Elfeldt R, Leimenstoll G, Westphal E, Schroeder P.

Transplant Proc. 1993 Apr;25(2):2131-2. No abstract available.

PMID:
8470292
11.

Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients.

Leimenstoll G, Zabel P, Schroeder P, Schlaak M, Niedermayer W.

Transplant Proc. 1993 Feb;25(1 Pt 1):561-3. No abstract available.

PMID:
8438414
12.

Antigenemia, immunoblotting, and enzyme immunoassay for early diagnosis of cytomegalovirus infection in renal transplant patients.

Fischer L, Rautenberg P, Bienengräber H, Leimenstoll G.

Transpl Int. 1993;6(4):201-5.

PMID:
8394090
13.

A microtitre assay system for glucocorticoid receptors: decreased receptor concentration in myocardial infarction.

Entzian P, Heer AH, Leimenstoll G, Barth J.

Scand J Clin Lab Invest. 1992 May;52(3):169-75.

PMID:
1411249
14.

Temporal patterns of immunoblot-reactive antibodies to cytomegalovirus in transplant recipients.

Rautenberg P, Meyer IC, Kaden J, Leimenstoll G, Engemann R.

Transpl Int. 1992 Mar;5(1):31-7.

PMID:
1316124
15.

Rejection prophylaxis with interleukin-2 receptor antibody BT 563: mechanisms of action on human cells.

Herwartz C, Steinmann J, Bethke U, Engemann R, Gassel J, Hoffmann S, Leimenstoll G, Timmermann W, Müller-Ruchholtz W.

Transpl Int. 1992;5 Suppl 1:S684-7.

PMID:
14621910
16.

Malignant lymphoma of donor origin after renal transplantation: a case report.

Gassel AM, Westphal E, Hansmann ML, Leimenstoll G, Gassel HJ.

Hum Pathol. 1991 Dec;22(12):1291-3.

PMID:
1748435
17.
18.

Discrepant results of different tests for antibodies to hepatitis C in children with malignant diseases and in patients on renal replacement therapy.

Rautenberg P, Schneppenheim R, Leimenstoll G, Behnke H, Loose G.

Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):978-81.

PMID:
1724423
19.

[Inferior vena cava compression syndrome in cystic kidney. Duplex ultrasonic diagnosis].

Leimenstoll G, Loose G, Harder T, Herrmann G, Papadopoulos I, Burck HC, Niedermayer W.

Dtsch Med Wochenschr. 1991 Oct 18;116(42):1583-7. German.

PMID:
1935624
20.

An antithymocyte globulin of rabbit origin inhibits the antigen-induced activation of alloreactive T cells by blocking CD2.

Leimenstoll G, Zerrenthin N, Niedermayer W, Steinmann J.

Transplant Proc. 1991 Feb;23(1 Pt 2):982-4. No abstract available.

PMID:
1671184
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk